We performed clinical studies on itraconazole, a new triazole antifungal agent. Four patients suffering from candidemia, pulmonary aspergillosis, oral thrush, and urinary tract infection due to Trichosporon cutaneum were treated with itraconazole at a single daily dose of 100-200 mg for 9-31 days. Clinical response was good in all patients. Bacteriological effect was eradicated in 2 cases, diminished in one and unknown in one. No side effect was observed and there were no abnormal laboratory findings. A suspected case of pulmonary cryptococcosis tolerated long-term administration of itraconazole at a daily dose of 100-150 mg for 198 days without observable adverse reactions.
!!!All Science Journal Classification (ASJC) codes